Gnubiotics Sciences SA

Gnubiotics Sciences SA is a Swiss biotechnology company dedicated to advancing pet health through innovative solutions, including their flagship product, AMObiome™, aimed at enhancing the gut microbiome of cats and dogs. Gnubiotics Sciences SA, founded in 2016 in Switzerland, specializes in the development of functional ingredients for pet health. The company was established by Bernardo Horta e Costa and has made two significant funding deals, with the most recent being a Series A round in July 2020, raising CHF 2. 6 million.

The company has not undergone notable pivots but has a clear focus on the pet health sector, with its headquarters located in Switzerland. Gnubiotics is focused on redefining pet health through its lead product, AMObiome™, an innovative functional ingredient designed to support the gut microbiome of cats and dogs. AMObiome™ is the first Animal Milk Oligosaccharide (AMO) ingredient that contains over 30 naturally occurring oligosaccharide structures, modeled after those found in the mothers' milk of these animals. This product is engineered to promote beneficial bacteria in the gut, thereby addressing issues such as gut dysbiosis and its associated symptoms, including irregular stool, vomiting, and low energy.

AMObiome™ has undergone rigorous clinical validation through multiple studies, demonstrating significant improvements in microbiome diversity and immune response. The product is distributed globally through a partnership with Archer Daniels Midland (ADM), targeting markets in the USA and Europe, with sales expected to launch in the first half of 2026. Gnubiotics operates within a B2B framework, primarily engaging with pet food and supplement producers to market and distribute AMObiome™. The company's revenue model is structured around exclusive global marketing and distribution agreements, allowing for strategic partnerships that enhance market penetration.

Transactions typically involve bulk orders of AMObiome™, facilitating integration into various pet food formats, including dry kibble, wet food, and supplements. The flagship product, AMObiome™, is positioned as a premium ingredient for manufacturers seeking to enhance gut health and immune support in their offerings. As the company prepares to launch its products, it is set to implement pricing strategies tailored to different customer segments within the pet industry, including established pet food brands and emerging supplement providers. Gnubiotics plans to leverage the CHF 0.

79 million raised in venture debt financing from UBS in July 2020 to support the development and launch of AMObiome™ in the first half of 2026. The company is targeting expansion into the USA and Europe, aiming to establish a strong market presence through its partnerships with major distributors. These initiatives are expected to enhance market access and drive growth in the rapidly evolving pet health sector.